Clinical Trial Update: Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease [NA]

View source ↗

Summary

The document reports expanded access use of Myozyme (alglucosidase alfa) in patients with Pompe disease. It notes that the program status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pompe Disease

Drugs mentioned

• Myozyme (alglucosidase alfa)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Glycogen Storage Disease Type II, Glycogenosis 2 | NA | Status: COMPLETED